Both enalapril and losartan demonstrate inhibitory effects on catecholamine secretion in the rat adrenal gland model.
Answers are grounded in this paper and cite their sources.
May indicate adrenal sympatholytic actions of ACEIs/ARBs; hypothesis-generating with no clinical implications yet.
The present study was attempted to compare enalapril, an angiotensin-converting enzyme inhibitor with losartan an angiotensin II (Ang II) receptor blocker in the inhibitory effects on the secretion of catecholamines (CA) from the perfused model of the rat adrenal gland. Methods: The adrenal gland was isolated and perfused with Krebs-bicarbonate. CA was measured directly by using the fluorospectrophotometer. Results: Both enalapril and losartan during perfusion into an adrenal vein for 90 minutes inhibited the CA release evoked by acetylcholine (ACh), 1.1-dimethyl-4-phenyl piperazinium (DMPP, a selective N n agonist), high K + (a direct membrane-depolarizer), 3-(m-chloro-phenyl-carbamoyl-oxy-2-butynyltrimethyl ammonium (McN-A-343, a selective M 1 agonist), and Ang II in a time-dependent manner. Also, in the presence of enalapril or losartan, the CA release evoked by veratridine (an activator of voltage-dependent Na + channels), 6-dimethyl-3-nitro-4-(2-trifluoromethyl phenyl)-pyridine-5-carboxylate (BAY-K-8644, an L-type Ca -2+ channel activator), and cyclopiazonic acid (a cytoplasmic Ca 2+ -ATPase inhibitor) were significantly reduced. Based on the same concentration of enalapril and losartan, for the CA release evoked by ACh, high K + , DMPP, McN-A-343, Ang II, veratridine,
No takes yet. Share an insight, caveat, or question.
Lim et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: